IRVINE, Calif. / Apr 30, 2024 / Business Wire / Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2024. “Our commercial team continued to execute at a high level in the first quarter, generating revenue growth of 29% year over year... Read More

IRVINE, Calif. / Mar 22, 2024 / Business Wire / Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today to adopt Axonics’ merger agreement with Boston Scientific Corporation (NYSE: BSX). According to preliminary voting results from the special meeting of stockholders held earlier today, a majority of the shares of Axonics’ common stock outstanding and entitled to vote at the special meeting voted in... Read More

IRVINE, Calif. / Mar 21, 2024 / Business Wire / Axonics, Inc. (Nasdaq: AXNX) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued written decisions on two Medtronic patents that Axonics is contesting. The PTAB issued its decision with respect to Patent Nos. 8,626,314 (“the ‘314 patent”) and 8,036,756 (“the ‘756 patent”). Medtronic has asserted these patents, which... Read More

IRVINE, Calif. / Mar 14, 2024 / Business Wire / Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Axonics R20™ rechargeable sacral neuromodulation (SNM) system has received CE Mark approval. The R20 neurostimulator is labeled for a functional life in the body of at least 20 years... Read More

IRVINE, Calif. / Feb 29, 2024 / Business Wire / Axonics, Inc. (Nasdaq: AXNX) today announced that it has received notice that Medtronic has filed a complaint with the U.S. International Trade Commission (ITC), along with a parallel action in U.S. District Court for the District of Delaware. The complaint alleges that Axonics infringes two Medtronic patents that purportedly relate to a “patient programmer with automated MRI... Read More

IRVINE, Calif. / Feb 28, 2024 / Business Wire / Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months and fiscal year ended December 31, 2023. “The continued strong performance of Axonics reflects the physician community’s preference and enthusiasm for our... Read More

IRVINE, Calif. / Jan 08, 2024 / Business Wire / Axonics, Inc. (Nasdaq: AXNX) today announced that it has entered into a definitive agreement to be acquired by Boston Scientific Corporation (NYSE: BSX) for $71 in cash per share, representing an equity value of approximately $3.7 billion. Axonics brings a complementary product portfolio to the Boston Scientific Urology business. Axonics has pioneered and introduced significant... Read More

IRVINE, Calif. / Jan 08, 2024 / Business Wire / Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 2023. “The continued strong performance of Axonics reflects the physician community’s preference and... Read More

IRVINE, Calif. / Dec 27, 2023 / Business Wire / Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to present at the J.P. Morgan Healthcare conference at 5:15 p.m. Pacific Time on Monday, January 8, 2024. Interested parties may access a live webcast and replay of the presentation by visiting... Read More

IRVINE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NeuroQure has embarked on a transformative journey aimed at revolutionizing the treatment landscape for Fragile X Syndrome and Autism Spectrum Disorder (ASD). With an unwavering commitment to addressing the monogenic origins of these conditions, NeuroQure, founded by businessman Dave Justus and renowned geneticist Dr. Jay Gargus , MD, Ph.D., is pioneering a path toward... Read More

IRVINE, Calif. / Nov 01, 2023 / Business Wire / Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following investor conferences in November: Event: Wolfe Research Healthcare Conference Date: Tuesday, November 14 Presentation time: 12:30 p.m. Eastern Time Event: Piper... Read More

Generated quarterly revenue of $93.1 million, an increase of 32% year over year Fiscal year 2023 revenue guidance increased to $362 million IRVINE, Calif. / Oct 30, 2023 / Business Wire / Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended... Read More

IRVINE, Calif. / Oct 02, 2023 / Business Wire / Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to report third quarter 2023 financial results after the close of trading on Monday, October 30. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. To... Read More

IRVINE, Calif. / Aug 25, 2023 / Business Wire / Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following investor conferences in September: Event: Wells Fargo Healthcare Conference Date: Friday, September 8 Presentation time: 10:15 a.m. Eastern Time Event: Morgan... Read More

IRVINE, Calif. / Aug 21, 2023 / Business Wire / Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Dan L. Dearen, president and chief financial officer, is retiring from the company. Kari Keese, vice president of finance and accounting, will succeed Mr. Dearen on Monday, October 2. “On... Read More

Generated quarterly revenue of $92.9 million, an increase of 35% year over year Fiscal year 2023 revenue guidance increased to $358 million IRVINE, Calif. / Jul 27, 2023 / Business Wire / Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended June 30,... Read More

IRVINE, Calif. / Jun 29, 2023 / Business Wire / Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2023 financial results after the close of trading on Thursday, July 27. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. To access the... Read More

Generated quarterly revenue of $70.7 million, an increase of 46% year over year Fiscal year 2023 revenue guidance increased to $348 million IRVINE, Calif. / May 01, 2023 / Business Wire / Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended March... Read More

IRVINE, Calif. / Apr 25, 2023 / Business Wire / Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following upcoming investor conferences: Event: BofA Securities Healthcare Conference Date: Tuesday, May 9 Time: 2:20 p.m. Eastern Time Event: RBC Capital Markets Healthcare... Read More

IRVINE, Calif. / Apr 24, 2023 / Business Wire / Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the acquisition of a lead placement solution from Radian, LLC that complements Axonics’ existing sacral neuromodulation (SNM) offering. Physicians determine a patient’s eligibility for... Read More

IRVINE, Calif. / Apr 10, 2023 / Business Wire / Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to report first quarter 2023 financial results after the close of trading on Monday, May 1. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. To access... Read More

IRVINE, Calif. / Mar 29, 2023 / Business Wire / Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced it ranked No. 2 on the Financial Times 2023 list of the fastest growing companies in the Americas. This follows the company’s No. 1 ranking on the 2022 list . Companies were ranked based on... Read More

IRVINE, Calif. / Mar 07, 2023 / Business Wire / Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is participating as a platinum sponsor of the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) 2023 Winter Meeting, which is being held in Nashville from March 7-11. Axonics... Read More

IRVINE, Calif. / Mar 01, 2023 / Business Wire / Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months and fiscal year ended December 31, 2022. “This quarter’s record results reflect the growing demand for our best-in-class incontinence products,” said... Read More

IRVINE, Calif. / Feb 08, 2023 / Business Wire / Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report fourth quarter 2022 financial results after the close of trading on Wednesday, March 1. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. Interested... Read More

IRVINE, Calif. / Jan 31, 2023 / Business Wire / Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the U.S. Food and Drug Administration has approved the company’s fourth-generation rechargeable sacral neuromodulation system. The newly approved Axonics R20 ™ neurostimulator is labeled... Read More

4Q22 total company net revenue expected to be $85.6 to $86.0 million, an increase of 61% y/y Fiscal year 2022 total company net revenue expected to be in the range of $273.6 million, an increase of 52% y/y Fiscal year 2023 revenue guidance of $342 million, an increase of 25% y/y Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder... Read More

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California. Axonics is scheduled to present at 4:30 p.m. Pacific Time on Wednesday, January 11. A live webcast and archived replay of the presentation will be accessible on... Read More

IRVINE, Calif.--( BUSINESS WIRE )-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Health Canada has approved the company’s fourth-generation rechargeable sacral neuromodulation system. The newly approved Axonics R20 ™ neurostimulator is labeled for a functional life in the body of... Read More